1,386 results on '"Bukh, Jens"'
Search Results
2. Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages
3. An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals
4. Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system
5. B-cell characteristics define HCV reinfection outcome
6. Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone
7. The effect of smartphone-based monitoring and treatment including clinical feedback versus smartphone-based monitoring without clinical feedback in bipolar disorder: the SmartBipolar trial—a study protocol for a randomized controlled parallel-group trial
8. Characterising the RNA-binding protein atlas of the mammalian brain uncovers RBM5 misregulation in mouse models of Huntington’s disease
9. Hepatitis C virus RNA is 5′-capped with flavin adenine dinucleotide
10. Mechanisms and Consequences of Genetic Variation in Hepatitis C Virus (HCV)
11. Renaming of the genus Flavivirus to Orthoflavivirus and extension of binomial species names within the family Flaviviridae
12. Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection
13. Personality disorders in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy control individuals
14. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
15. Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment
16. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers
17. JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization
18. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1
19. Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2
20. Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice
21. Structure of the hepatitis C virus E1/E2 envelope proteins in a homodimeric complex
22. Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations
23. In vitro efficacy of artemisinin-based treatments against SARS-CoV-2
24. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
25. Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.
26. Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an in vivo infectious 3b cDNA clone
27. Novel, broad and potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages
28. Hepatitis C virus alters the morphology and function of peroxisomes
29. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
30. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models
31. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape Variants
32. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
33. Evidence for Cross-Genotype Neutralization of Hepatitis C Virus Pseudo-Particles and Enhancement of Infectivity by Apolipoprotein C1
34. Mouse models of acute and chronic hepacivirus infection
35. The effect of smartphone-based monitoring and treatment including clinical feedback versus smartphone-based monitoring without clinical feedback in bipolar disorder: the SmartBipolar Trial - A study protocol for a randomised controlled parallel-group trial
36. Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model
37. Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice
38. Pre‐existing, treatment‐specific resistance‐associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct‐acting antivirals
39. Low intraindividual viral evolution is linked to disease progression and need of antiviral treatment initiation in chronic hepatitis B
40. In vitro Assay for Neutralizing Antibody to Hepatitis C Virus: Evidence for Broadly Conserved Neutralization Epitopes
41. The p7 Polypeptide of Hepatitis C Virus Is Critical for Infectivity and Contains Functionally Important Genotype-Specific Sequences
42. Genomic Analysis of the Host Response to Hepatitis C Virus Infection
43. Viral and Immunological Determinants of Hepatitis C Virus Clearance, Persistence, and Disease
44. Mutations That Permit Efficient Replication of Hepatitis C Virus RNA in Huh-7 Cells Prevent Productive Replication in Chimpanzees
45. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine
46. A Virus Discovery Method Incorporating DNase Treatment and Its Application to the Identification of Two Bovine Parvovirus Species
47. Hepatitis C Virus Lacking the Hypervariable Region 1 of the Second Envelope Protein Is Infectious and Causes Acute Resolving or Persistent Infection in Chimpanzees
48. In Vitro Neutralization Assay Using Cultured Hepatitis C Virus
49. Full-Length Open Reading Frame Amplification of Hepatitis C Virus
50. In vivo Analysis of the 3 ′ Untranslated Region of the Hepatitis C Virus after in vitro Mutagenesis of an Infectious cDNA Clone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.